Myocarditis and pericarditis in association with COVID-19 mRNA-vaccination: cases from a regional pharmacovigilance centre

• Published in: Global Cardiology Science & Practice Vol. 2021; no. 3; p. e202118
• Main Authors: Istampoulouoglou, Ioanna, Dimitriou, Georgios, Späni, Selina, Christ, Andreas, Zimmermanns, Barbara, Koechlin, Sarah, Stoeckmann, Oliver, Winterhalder, Clemens, Marono, David, Toma, Valeriu, Leuppi-Taegtmeyer, Anne B
• Format: Journal Article
• Language: English
• Published: UK Magdi Yacoub Heart Foundation 30.10.2021
• Subjects: Pharmacovigilance
• ISSN: 2305-7823; 2305-7823
• DOI: 10.21542/gcsp.2021.18

In this article we summarize suspected adverse events following immunization (AEFI) of pericarditis, myocarditis and perimyocarditis that were reported by our regional pharmacovigilance centre after COVID-19 mRNA-vaccination and discuss their association with these vaccines. Seventeen cases were reported between March and July 2021. Of these, nine had perimyocarditis, five myocarditis and three pericarditis. Twelve patients were male (71 %). The median age was 38 years (range 17 - 88). The most commonly observed presenting symptom was acute chest pain (65%). While 47% of the patients were previously healthy, 53% had at least one pre-existing comorbidity, with hypertension being the most prevalent (24%). The European Society of Cardiology diagnostic criteria for the reported AEFIs were fulfilled in twelve cases (71%). The AEFIs occurred after the first vaccine dose in six cases (35%), after the second vaccine dose in ten cases (59%) and after both doses in one case (6%). The median latency of all AEFIs taken together was 14 days (range 1 - 28) after the first vaccination and 3 days (range 1 - 17) after the second one. All patients except one were hospitalized (94%) with a median length of stay of 7.5 days (range 3 - 13). The majority of patients (n = 11, 65%) did not experience any complications, and 13 (77%) of the patients were recovered or recovering at the time of discharge. In 16 of the 17 cases (94%), the association between the AEFI and mRNA-vaccination was considered possible by the pharmacovigilance centre.